RIVAROXABAN | A208544 | AUROBINDO PHARMA LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2025-05-21 | Terminated 2025-12-10 | — | |
| D. Del. | 2023-12-01 | Terminated 2024-05-10 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.7967
per ea
Lowest NADAC/Unit
$0.7967
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 59651084918RIVAROXABAN 2.5 MG TABLET | $0.7967 | EA | Generic | — | 2026-06-17 |
| 59651084960RIVAROXABAN 2.5 MG TABLET | $0.7967 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.